TNFRSF17 and plasma cell myeloma: Ongoing trials (NCT02546167) involving CARs that target B cell maturation antigen (BCMA or CD269) in advanced myeloma have successfully eradicated both the malignant myeloma cells and the nonmalignant plasma cells that express BCMA (208).